(CVSA) Covista - Overview

Sector: Consumer Defensive | Industry: Education & Training Services | Exchange: NYSE (USA) | Market Cap: 4.132m USD | Total Return: -9.2% in 12m

Nursing Degrees, Medical Education, Veterinary Medicine, Online Certifications
Total Rating 68
Safety 84
Buy Signal 0.58
Education & Training Services
Industry Rotation: +8.9
Market Cap: 4.13B
Avg Turnover: 32.0M
Risk 3d forecast
Volatility46.4%
VaR 5th Pctl6.70%
VaR vs Median-17.6%
Reward TTM
Sharpe Ratio-0.04
Rel. Str. IBD49.3
Rel. Str. Peer Group70
Character TTM
Beta0.751
Beta Downside0.794
Hurst Exponent0.607
Drawdowns 3y
Max DD42.14%
CAGR/Max DD0.95
CAGR/Mean DD3.55
EPS (Earnings per Share) EPS (Earnings per Share) of CVSA over the last years for every Quarter: "2021-03": 0.72, "2021-06": 0.7, "2021-09": 0.62, "2021-12": 0.75, "2022-03": 0.87, "2022-06": 1.31, "2022-09": 0.88, "2022-12": 1.17, "2023-03": 1.13, "2023-06": 1.03, "2023-09": 0.93, "2023-12": 1.23, "2024-03": 1.5, "2024-06": 1.37, "2024-09": 1.29, "2024-12": 1.81, "2025-03": 1.92, "2025-06": 1.66, "2025-09": 1.75, "2025-12": 2.43, "2026-03": 1.98,
EPS CAGR: 29.19%
EPS Trend: 99.2%
Last SUE: 2.22
Qual. Beats: 10
Revenue Revenue of CVSA over the last years for every Quarter: 2021-03: 230.213, 2021-06: 223.466, 2021-09: 289.07, 2021-12: 371.198, 2022-03: 365.623, 2022-06: 360.647, 2022-09: 354.269, 2022-12: 362.834, 2023-03: 369.082, 2023-06: 364.641, 2023-09: 368.845, 2023-12: 393.242, 2024-03: 412.658, 2024-06: 409.907, 2024-09: 417.4, 2024-12: 447.729, 2025-03: 466.055, 2025-06: 457.106, 2025-09: 462.288, 2025-12: 503.385, 2026-03: 487.03,
Rev. CAGR: 11.52%
Rev. Trend: 99.7%
Last SUE: 3.21
Qual. Beats: 10

Warnings

Below Avwap Earnings

Tailwinds

Idiosyncratic Leader, Pead, Garp

Description: CVSA Covista

Covista Inc. (NYSE: CVSA), formerly Adtalem Global Education Inc., is a diversified healthcare education provider operating across the United States and the Caribbean. The company manages a portfolio of institutions including Chamberlain University and Walden University, offering a range of degree and certificate programs in nursing, medicine, veterinary science, and behavioral health. Its business model relies heavily on the integration of online and on-campus instruction to serve the high-demand professional healthcare sector.

The education services industry often experiences counter-cyclical growth, as professional certification requirements and workforce shortages in nursing and medicine drive enrollment. Covista’s focus on specialized medical and veterinary training requires significant capital investment in clinical partnerships and accreditation compliance. For a deeper look at the companys valuation metrics, consider checking the latest data on ValueRay.

Headquartered in Chicago and incorporated in 1987, the company operates through three primary segments: Chamberlain, Walden, and Medical and Veterinary. These divisions provide postsecondary education ranging from bachelors degrees to doctoral programs, targeting critical infrastructure roles in public health, social work, and information technology.

Headlines to Watch Out For
  • Nursing enrollment growth at Chamberlain drives core revenue and margin expansion
  • Higher interest rates increase debt servicing costs for academic facility expansion
  • Federal student aid regulatory changes impact tuition funding and enrollment volume
  • Healthcare labor shortages increase demand for medical and veterinary degree programs
  • Integration of Walden University online programs scales operational efficiency and profitability
Piotroski VR-10 (Strict) 9.0
Net Income: 234.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.87 > 1.0
NWC/Revenue: -9.25% < 20% (prev -5.18%; Δ -4.07% < -1%)
CFO/TA 0.15 > 3% & CFO 406.2m > Net Income 234.1m
Net Debt (824.3m) to EBITDA (431.3m): 1.91 < 3
Current Ratio: 0.70 > 1.5 & < 3
Outstanding Shares: last quarter (34.8m) vs 12m ago -9.03% < -2%
Gross Margin: 57.28% > 18% (prev 0.57%; Δ 5.67k% > 0.5%)
Asset Turnover: 69.11% > 50% (prev 62.41%; Δ 6.70% > 0%)
Interest Coverage Ratio: 7.97 > 6 (EBITDA TTM 431.3m / Interest Expense TTM 46.5m)
Altman Z'' 6.26
A: -0.06 (Total Current Assets 403.8m - Total Current Liabilities 580.4m) / Total Assets 2.74b
B: 1.08 (Retained Earnings 2.96b / Total Assets 2.74b)
C: 0.13 (EBIT TTM 370.5m / Avg Total Assets 2.76b)
D: 2.15 (Book Value of Equity 2.96b / Total Liabilities 1.37b)
Altman-Z'' = 6.26 = AAA
Beneish M -3.03
DSRI: 0.98 (Receivables 175.9m/163.0m, Revenue 1.91b/1.74b)
GMI: 1.00 (GM 57.28% / 57.33%)
AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.68)
SGI: 1.10 (Revenue 1.91b / 1.74b)
TATA: -0.06 (NI 234.1m - CFO 406.2m) / TA 2.74b)
Beneish M = -3.03 (Cap -4..+1) = AA
What is the price of CVSA shares?

As of May 31, 2026, the stock is trading at USD 117.80 with a total of 265,878 shares traded.
Over the past week, the price has changed by -5.06%, over one month by +2.77%, over three months by +20.20% and over the past year by -9.24%.

Is CVSA a buy, sell or hold?

Covista has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CVSA.

  • StrongBuy: 2
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CVSA price?
Analysts Target Price 156.3 32.6%
Covista (CVSA) - Fundamental Data Overview as of 30 May 2026
Market Cap USD = 4.13b (4.13b USD * 1.0 USD.USD)
P/E Trailing = 17.6739
P/E Forward = 13.6986
P/S = 2.1636
P/B = 3.0571
P/EG = 0.9128
Revenue TTM = 1.91b USD
EBIT TTM = 370.5m USD
EBITDA TTM = 431.3m USD
Long Term Debt = 495.6m USD (from longTermDebt, last quarter)
Short Term Debt = 39.1m USD (from shortTermDebt, last quarter)
Debt = 973.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 236.8m
Net Debt = 824.3m USD (calculated: Debt 973.1m - CCE 148.8m)
Enterprise Value = 4.96b USD (4.13b + Debt 973.1m - CCE 148.8m)
Interest Coverage Ratio = 7.97 (Ebit TTM 370.5m / Interest Expense TTM 46.5m)
EV/FCF = 14.74x (Enterprise Value 4.96b / FCF TTM 336.3m)
FCF Yield = 6.78% (FCF TTM 336.3m / Enterprise Value 4.96b)
FCF Margin = 17.61% (FCF TTM 336.3m / Revenue TTM 1.91b)
Net Margin = 12.26% (Net Income TTM 234.1m / Revenue TTM 1.91b)
Gross Margin = 57.28% ((Revenue TTM 1.91b - Cost of Revenue TTM 815.8m) / Revenue TTM)
Gross Margin QoQ = 56.73% (prev 59.19%)
Tobins Q-Ratio = 1.81 (Enterprise Value 4.96b / Total Assets 2.74b)
Interest Expense / Debt = 4.78% (Interest Expense 46.5m / Debt 973.1m)
Taxrate = 25.61% (20.0m / 77.9m)
NOPAT = 275.6m (EBIT 370.5m * (1 - 25.61%))
Current Ratio = 0.70 (Total Current Assets 403.8m / Total Current Liabilities 580.4m)
Debt / Equity = 0.71 (Debt 973.1m / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = 1.91 (Net Debt 824.3m / EBITDA 431.3m)
Debt / FCF = 2.45 (Net Debt 824.3m / FCF TTM 336.3m)
Total Stockholder Equity = 1.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.47% (Net Income 234.1m / Total Assets 2.74b)
RoE = 16.62% (Net Income TTM 234.1m / Total Stockholder Equity 1.41b)
RoCE = 19.46% (EBIT 370.5m / Capital Employed (Equity 1.41b + L.T.Debt 495.6m))
RoIC = 13.46% (NOPAT 275.6m / Invested Capital 2.05b)
WACC = 7.66% (E(4.13b)/V(5.11b) * Re(8.63%) + D(973.1m)/V(5.11b) * Rd(4.78%) * (1-Tc(0.26)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -6.83%
[DCF] Terminal Value 77.97% ; FCFF base≈318.0m ; Y1≈364.5m ; Y5≈536.5m
[DCF] Fair Price = 213.0 (EV 8.07b - Net Debt 824.3m = Equity 7.25b / Shares 34.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.19 | EPS CAGR: 29.19% | SUE: 2.22 | # QB: 10
Revenue Correlation: 99.70 | Revenue CAGR: 11.52% | SUE: 3.21 | # QB: 10
EPS next Quarter (2026-09-30): EPS=1.80 | Chg30d=-0.55% | Revisions=-20% | Analysts=2
EPS current Year (2026-06-30): EPS=8.02 | Chg30d=+1.40% | Revisions=+20% | GrowthEPS=+20.2% | GrowthRev=+8.2%
EPS next Year (2027-06-30): EPS=8.84 | Chg30d=+0.94% | Revisions=+33% | GrowthEPS=+10.3% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: +33%